Cms grants transitional pass-through payment for medtronic symplicity spyral™ renal denervation catheter

The symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure  galway, ireland , nov. 1, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced that the centers for medicare & medicaid services (cms) has granted transitional pass-through (tpt) payment for the medtronic symplicity spyral™ renal denervation (rdn) catheter, used in the symplicity™ blood pressure procedure, under the medicare hospital outpatient prospective payment system. tpt payment, which will be effective for up to three years beginning january 1, 2025, aims to support patient access to new and innovative technology, including devices granted breakthrough device designations like the symplicity spyral rdn system.
MDT Ratings Summary
MDT Quant Ranking